<DOC>
	<DOCNO>NCT01971515</DOCNO>
	<brief_summary>This Phase 1 , first-in-human , open-label , non-randomized , dose escalation , trial explore safety , tolerability , pharmacokinetic ( PK ) , pharmacodynamic ( PD ) clinical activity signal MSC2363318A .</brief_summary>
	<brief_title>First-in-Human Dose Escalation Trial Subjects With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Age great equal ( &gt; = ) 18 year Confirmed diagnosis advanced malignancy may control p70S6K Akt inhibition base already identify molecular alteration know affect PAM pathway , : : : : phosphate tensin homolog ( PTEN ) , phosphoinositide 3Kinase catalytic subunit alpha isoform ( PI3KCA ) , protein kinase B 1 ( Akt 1 ) , Akt 3 , mammalian target rapamycin ( mTOR ) , tumor sclerosis complex 1 ( TSC1 ) , tumor sclerosis complex 2 ( TSC2 ) , subject receive least treatment option consider standard therapy , unless available treatment acceptable subject . For dose escalation portion trial , subject must receive standard therapy unless intolerant contraindicate . Part 2 , Cohort 1 : For subject PAM pathway alteration , subject must PAM alteration , exclude Akt2 activate mutation amplification , confound genomic alteration . Part 2 , Cohort 2 : Histologically confirm local laboratory testing ( immunohistochemistry 3+ stain and/or fluorescence situ hybridization ratio â‰¥ 2.0 ) HER2+ metastatic breast cancer subject resistant trastuzumabcontaining treatment progress trastuzumab , pertuzumab , taxane , and/or trastuzumab emtansine . There limit regard number prior line therapy . Part 2 , Cohort 3 : Histologically and/or cytologically confirm diagnosis breast cancer hormone receptorpositive status ( ER and/or PgR positive ) HER2negative status prior exposure tamoxifen and/or aromatase inhibitor and/or aromatase inhibitor plus palbociclib . Prior treatment tamoxifen neoadjuvant setting allow must discontinue least 1 year prior first dose . Measurable disease use clinically appropriate criterion type malignancy , RECIST version 1.1 solid tumor Cheson 2007 lymphoma A tumor accessible biopsy consent undergo tumor biopsy MSC2363318A treatment Ability read understand inform consent form willingness ability give inform consent demonstrate comprehension trial undergo trial activity Negative blood pregnancy test screen visit woman childbearing potential Willingness avoid pregnancy breast feed begin two week first MSC2363318A dose end three month last trial treatment . Male subject female partner childbearing potential female subject childbearing potential must use adequate contraception judgment Investigator , two barrier method one barrier method spermicide intrauterine device Eastern Cooperative Oncology Group Performance Status &gt; =2 Previous therapy : Previous treatment currently malignancy PAM Pathway Inhibitor Chemotherapy , immunotherapy , hormonal therapy ( except low dose corticosteroid ) , biologic therapy , anticancer therapy within 1 month ( five elimination halflives noncytotoxics , whichever short ) Day 1 trial drug treatment ( 6 week nitrosureas mitomycin Any investigational agent within 28 day Day 1 trial drug treatment Extensive prior radiotherapy 30 percent bone marrow reserve , prior bone marrow/stem cell transplantation within 5 year enrolment Known tumor EGFR , KRAS , and/or Akt2 mutation amplification Ongoing toxicity ( except alopecia ) due prior therapy , unless return baseline Grade 1 less Major surgical intervention participation therapeutic clinical trial within 28 day Day 1 first dose MSC2363318A Bone marrow impairment , renal impairment , liver function abnormality impair cardiac function define protocol History cerebral vascular accident stroke within previous 2 year Uncontrolled hypertension History Grade 3 4 allergic reaction attribute compound similar chemical biologic composition MSC2363318A Known active central nervous system ( CNS ) metastases History difficulty swallowing , malabsorption chronic gastrointestinal disease condition may hamper compliance and/or absorption investigational product Known human immunodeficiency virus , viral hepatitis , tuberculosis positivity Legal incapacity limit legal capacity Any condition , opinion Investigator , might impair subject 's tolerance trial treatment , safety individual subject outcome trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MSC2363318A</keyword>
	<keyword>Maximum tolerate dose</keyword>
	<keyword>Dose limit toxicity</keyword>
	<keyword>Recommended phase 2 dose</keyword>
	<keyword>M2698</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>HER2+ Metastatic Breast Cancer</keyword>
	<keyword>Hormone refractory ER/PR+ breast cancer</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>PAM Pathway Alteration ( )</keyword>
	<keyword>PAM Pathway</keyword>
	<keyword>Targeted Therapy</keyword>
	<keyword>P70S6K</keyword>
	<keyword>AKT Inhibition</keyword>
	<keyword>PI3K Pathway</keyword>
	<keyword>HER2+ Trastuzumab Resistance</keyword>
</DOC>